Table 2.
Staging after review and causes of change in management
| Initial stage (n) | Review stage n (%) | Change in management after review, n (%) | Causes of change in management | |
|---|---|---|---|---|
| CIS=3 | Remained CIS | 2 (66.7%) | 0 | |
| Upstaged to T1 | 0 | |||
| Upstaged to T2 | 1 (33.3%) | 1 (100%) | Review showed MIBC + LVI | |
| Ta=5 | Remained Ta | 3 (60.0%) | 0 | |
| Upstaged to T1 | 1 (20.0%) | 1 (100%) | Change in T category + CIS 1 (100%) | |
| Upstaged to T2 | 1 (20.0%) | 1 (100%) | Change in T category 1 (100%) | |
| T1=28 | Remained T1 | 19 (67.9%) | 6 (31.6%) | CIS found on review 5 (83.3%) |
| LVI found on review 1 (16.7%) | ||||
| Upstaged to T2 | 8 (28.6%) | 8 (100%) | Change in T category 8 (100%) | |
| Downstaged to Ta | 1 (3.6%) | 0 | ||
| T2=55 | Remained T2 | 54 (98.2%) | 16 (29.6%) | LVI found on review 6 (37.5%) |
| Variant histology on review 2 (12.5%) | ||||
| LVI+ variant on review 3 (18.8%) | ||||
| Change in histologic diagnosis 2 (12.5%) | ||||
| Unsure if MP present/invaded 3 (18.8%) | ||||
| Downstaged to T1 | 1 (1.8%) | 1 (100%) | No MP invasion on review | |
CIS: carcinoma in situ; LVI: lymphovascular invasion; MIBC: muscle-invasive bladder cancer; MP: muscularis propria.